Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
Adrianus J. de Langen, Melissa L. Johnson, Julien Mazières, Anne‐Marie C. Dingemans, Giannis Mountzios, Miklos Pless, Jürgen Wolf, Martin Schüler, H. Léna, Ferdinandos Skoulidis, Yasuto Yoneshima, Sang‐We Kim, Helena Linardou, Silvia Novello, Anthonie J. van der Wekken, Yuanbin Chen, Solange Peters, Enriqueta Felip, Benjamin Solomon, Suresh S. Ramalingam, Christophe Dooms, Colin R. Lindsay, Carlos Gil Ferreira, Normand Blais, Cynthia C. Obiozor, Yang Wang, Bhakti Mehta, Tracy Varrieur, Gataree Ngarmchamnanrith, Björn Stollenwerk, David Waterhouse, Luis Paz‐Ares
Topics & Concepts
DocetaxelMedicineInternal medicineOncologyLung cancerCancerTaxaneProgressive diseaseChemotherapyBreast cancerLung Cancer Treatments and MutationsLung Cancer Research StudiesLung Cancer Diagnosis and Treatment